ATE76753T1 - Pharmazeutische zusammensetzung zur intranasalen verabreichung, die ghrh, einen cholinergischen agonisten und gegebenenfalls ein gallensalz enthaelt. - Google Patents

Pharmazeutische zusammensetzung zur intranasalen verabreichung, die ghrh, einen cholinergischen agonisten und gegebenenfalls ein gallensalz enthaelt.

Info

Publication number
ATE76753T1
ATE76753T1 AT88111657T AT88111657T ATE76753T1 AT E76753 T1 ATE76753 T1 AT E76753T1 AT 88111657 T AT88111657 T AT 88111657T AT 88111657 T AT88111657 T AT 88111657T AT E76753 T1 ATE76753 T1 AT E76753T1
Authority
AT
Austria
Prior art keywords
pharmaceutical composition
intranasal administration
optionally
bile salt
cholinergic agonist
Prior art date
Application number
AT88111657T
Other languages
English (en)
Inventor
Franco Camanni
Soldato Piero Del
Ezio Ghigo
Eugenio E Muller
Boghen M Franklin
Original Assignee
Pierrel Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pierrel Spa filed Critical Pierrel Spa
Application granted granted Critical
Publication of ATE76753T1 publication Critical patent/ATE76753T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT88111657T 1987-07-30 1988-07-20 Pharmazeutische zusammensetzung zur intranasalen verabreichung, die ghrh, einen cholinergischen agonisten und gegebenenfalls ein gallensalz enthaelt. ATE76753T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT21513/87A IT1222395B (it) 1987-07-30 1987-07-30 Composizione farmaceutica per somministrazione intranasale comprendente l'ormone ghrh,un agonista colinergico e/o un sale biliare
EP88111657A EP0301392B1 (en) 1987-07-30 1988-07-20 Pharmaceutical composition for intranasal administration comprising gh - releasing hormone, a cholinergic agonist and in case a bile salt

Publications (1)

Publication Number Publication Date
ATE76753T1 true ATE76753T1 (de) 1992-06-15

Family

ID=11182925

Family Applications (1)

Application Number Title Priority Date Filing Date
AT88111657T ATE76753T1 (de) 1987-07-30 1988-07-20 Pharmazeutische zusammensetzung zur intranasalen verabreichung, die ghrh, einen cholinergischen agonisten und gegebenenfalls ein gallensalz enthaelt.

Country Status (12)

Country Link
US (1) US5010056A (de)
EP (1) EP0301392B1 (de)
JP (1) JPS6450823A (de)
KR (1) KR890001584A (de)
AT (1) ATE76753T1 (de)
AU (1) AU618547B2 (de)
DK (1) DK393188A (de)
IT (1) IT1222395B (de)
NO (1) NO883200L (de)
NZ (1) NZ225546A (de)
PH (1) PH26712A (de)
ZA (1) ZA885417B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0383931A (ja) * 1989-08-29 1991-04-09 Sumitomo Pharmaceut Co Ltd 低刺激性ｇｒｆ経鼻投与製剤
EP0432431B1 (de) * 1989-11-16 1993-06-16 PHIDEA S.p.A. Flüssige Arzneimittel zur nasalen Anwendung, die ein Polypeptid als Wirksubstanz enthalten
US5502067A (en) * 1994-02-04 1996-03-26 Morgan; Julia A. Treating apneahypopnea/snoring in humans
US5500205A (en) * 1994-02-23 1996-03-19 Enviro Pac International, L.I.C. Lachrymator aerosol formulations
US5861431A (en) * 1995-06-07 1999-01-19 Iotek, Inc. Incontinence treatment
AUPN801296A0 (en) 1996-02-12 1996-03-07 Csl Limited Stabilised growth hormone formulation and method of preparation thereof
US8048875B1 (en) 1997-02-24 2011-11-01 S.L.A. Pharma Ag Topical pharmaceutical composition comprising a cholinergic agent or a calcium channel blocker
CN1127333C (zh) * 1997-02-24 2003-11-12 S.L.A.药业股份公司 含有胆碱能药物或钙通道阻滞剂的局部用医药组合物
ATE289825T1 (de) * 1999-04-21 2005-03-15 1355540 Ontario Inc Methacoline oder histamine formulierungen zur feststellung von asthma
JP2005505491A (ja) * 1999-06-02 2005-02-24 ヘキサル・アクチェンゲゼルシャフト 水溶性活性物質の鼻腔内投与用医薬組成物
WO2001041732A1 (en) * 1999-12-06 2001-06-14 Gore Stanley L Compositions and methods for intranasal delivery of active agents to the brain
JP3498041B2 (ja) 2000-05-29 2004-02-16 科研製薬株式会社 プラルモレリン含有点鼻用製剤
US8299079B2 (en) * 2009-05-22 2012-10-30 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
US20100298335A1 (en) * 2009-05-22 2010-11-25 Kaufman Herbert E Preparations and Methods for Ameliorating or Reducing Presbyopia
EP3027637B1 (de) * 2013-08-01 2019-10-09 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Das glycin konjugat von beta-muricholsäure als hemmer des fxr-rezeptors zur behandlung von adipositas, insulinresistenz oder nicht alkoholischen fettlebererkrankung (nafld)
EP4203958A4 (de) * 2020-08-26 2024-10-09 Oticara, Inc. Zusammensetzungen, vorrichtungen und verfahren zur behandlung von nasen-, ohren- und anderen gewebeinfektionen und/oder -entzündungen

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ206518A (en) * 1982-12-10 1989-06-28 Syntex Inc Nasal composition comprising nona- or deca-peptide lhrh analogue and bile acid surfactant
JPS59163313A (ja) * 1983-03-09 1984-09-14 Teijin Ltd 経鼻投与用ペプチドホルモン類組成物
IT1169873B (it) * 1983-10-21 1987-06-03 Prodotti Formenti Srl Composizione farmaceutica ad attivita' sistemica anticolinesterasica, agonista-colinergica ed antimuscarinica
US4818531A (en) * 1985-02-06 1989-04-04 Eli Lilly And Company Growth hormone and thyroid hormone
JPS62126135A (ja) * 1985-11-25 1987-06-08 Sumitomo Pharmaceut Co Ltd 経鼻投与用ｇｒｆ製剤
US4663318A (en) * 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
US4880778A (en) * 1986-05-12 1989-11-14 Eastman Kodak Company Combinations having synergistic growth hormone releasing activity and methods for use thereof

Also Published As

Publication number Publication date
EP0301392A1 (de) 1989-02-01
DK393188D0 (da) 1988-07-14
AU2005188A (en) 1989-02-02
NZ225546A (en) 1990-12-21
EP0301392B1 (en) 1992-06-03
NO883200D0 (no) 1988-07-19
KR890001584A (ko) 1989-03-27
AU618547B2 (en) 1992-01-02
DK393188A (da) 1989-01-31
NO883200L (no) 1989-01-31
IT8721513A0 (it) 1987-07-30
IT1222395B (it) 1990-09-05
ZA885417B (en) 1989-06-28
PH26712A (en) 1992-09-15
JPS6450823A (en) 1989-02-27
US5010056A (en) 1991-04-23

Similar Documents

Publication Publication Date Title
DE59009462D1 (de) Implantierbare Vorrichtung zur dosierten Abgabe von Medikamenten in den menschlichen Körper.
ES2097155T3 (es) Forma de dosificacion efervescente y metodo de administracion.
SG52690A1 (en) Process for the production of biologically active protein (e.g. tgf)
MY112915A (en) Multiple unit tableted dosage form 1
ATE126433T1 (de) Verwendung von gamma-hydroxy-buttersäuresalzen zur herstellung von pharmazeutischen zusammensetzungen zur verwendung bei der behandlung von alkoholismus und die hergestellten zusammensetzungen.
EP0379806A3 (de) Pyrimidine und deren pharmazeutisch brauchbare Salze und deren Verwendung als Arzneimittel
MY128809A (en) Pharmaceutical formulation of omeprazole
DE69113470D1 (de) Intraokulares und intraorbitales Implantat zur kontrollierten Zuführung von Arzneimitteln.
MY103352A (en) Piperazinyl-heterocyclic compounds
ATE84215T1 (de) Arzneizubereitung zur oralen anwendung.
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
MX9704030A (es) 1,1-dioxidos de 2-heterocicliloxi y tiometil-1,2,5-tiadiazolidin-3-ona y composiciones y metodo de uso de los mismos.
ATE398618T1 (de) Pharmazeutische zusammensetzungen zur behandlung von zns und anderen krankheiten
ATE131050T1 (de) Matrixtablette zur verlängerten indapamidfreisetzung nach oraler gabe.
DE3680578D1 (de) Dipeptid-derivate, verfahren zur herstellung, pharmazeutische zusammensetzungen und ihre anwendung.
EP0348353A3 (en) The use of physiologically active substances for the manufacture of drugs for cerebral and neuronal diseases
DK393188A (da) Farmaceutisk praeparat til intranasal administrering
FI972308A0 (fi) 2-substituoituja 1,2,5-tiadiatsolidin-3-oni-1,1-dioksideja ja niitä sisältäviä koostumuksia ja menetelmiä niiden käyttämiseksi
DE69232016D1 (de) Pharmazeutische zusammensetzung, die gamma-hydroxybuttersäure oder das entsprechende lakton enthält, zur behandlung von drogenabhängigkeit und ernährungsstörungen
MY103210A (en) Arylpiperazinyl-alkylene-phenyl-heterocyclic compounds.
DK325289A (da) Strontiumsalt, fremgangsmaade til fremstilling heraf samt farmaceutiske midler indeholdende saltet
SE8802323D0 (sv) 8alfa-acylaminoergoline, its preparation and pharmaceutical compositions containing it
DE69009765D1 (de) Kynurensäurederivate, deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
JO1821B1 (en) New pharmaceutical product
DE68910021D1 (de) Oxaminsäureverbindungen und pharmazeutische Zusammensetzungen zur Anwendung bei der Verbesserung geschädigter Hirnfunktionen.